This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Adedoyin, A.
Right arrow Articles by Branch, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Adedoyin, A.
Right arrow Articles by Branch, R. A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2000, p. 2900-2902, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients with Definite or Probable Systemic Fungal Infections

Adedayo Adedoyin,1,dagger Christine E. Swenson,2 Lois E. Bolcsak,2 Andrzej Hellmann,3 Danuta Radowska,4 Gary Horwith,2 Andrew S. Janoff,2 and Robert A. Branch1,*

Center for Clinical Pharmacology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania1; The Liposome Company, Inc., Princeton, New Jersey2; and Hematology Department, Medical University of Gdansk,3 and Provincial Hospital of Infectious Diseases,4 Gdansk, Poland

Received 6 August 1999/Returned for modification 23 January 2000/Accepted 20 May 2000

This study describes a pharmacokinetic evaluation of amphotericin B (AMB) lipid complex injection (ABLC or Abelcet) in 17 patients with systemic fungal infection administered 5 mg/kg of body weight/day by infusion for 10 to 17 days. The results showed that AMB exhibited multiexponential disposition with high clearance, large volume of distribution at steady state, and long apparent elimination half-life but no evidence of accumulation in the blood after multiple daily doses. The results confirm previous observations and further reinforce the suggestion that ABLC may exist as a depot in the tissues from which free AMB is slowly released to limit exposure.

* Corresponding author. Mailing address: Center for Clinical Pharmacology, 623 Scaife Hall, University of Pittsburgh Medical Center, 200 Lothrop St., Pittsburgh, PA 15213-2582. Phone: (412) 648-2380. Fax: (412) 648-1837. E-mail: Branch{at}med1.dept-med.pitt.edu.

dagger Present address: Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Wilmington, DE.

Antimicrobial Agents and Chemotherapy, October 2000, p. 2900-2902, Vol. 44, No. 10
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lewis, R. E., Liao, G., Hou, J., Chamilos, G., Prince, R. A., Kontoyiannis, D. P. (2007). Comparative Analysis of Amphotericin B Lipid Complex and Liposomal Amphotericin B Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. Antimicrob. Agents Chemother. 51: 1253-1258 [Abstract] [Full Text]  
  • Wurthwein, G., Groll, A. H., Hempel, G., Adler-Shohet, F. C., Lieberman, J. M., Walsh, T. J. (2005). Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates. Antimicrob. Agents Chemother. 49: 5092-5098 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»